Skip to main content

Meningococcal Antigen Typing System (MATS): A Tool to Estimate Global Coverage for 4CMenB, a Multicomponent Meningococcal B Vaccine

  • Protocol
  • First Online:

Part of the book series: Methods in Molecular Biology ((MIMB,volume 1969))

Abstract

Meningococcal Antigen Typing System (MATS) is the combination of a sandwich ELISA (Enzyme Linked Immunosorbent Assay) developed to estimate the level of expression and immunoreactivity of the antigen components (fHbp, NHBA, and NadA) of the 4CMenB vaccine (Bexsero, GSK Vaccines) in circulating, serogroup B meningococcal (MenB) strains, with the molecular typing of PorA, the main antigenic component in the outer membrane vesicles (OMV). MATS has been proven to be a good surrogate of the accepted correlate of protection for meningococcus (hSBA), thus providing a quick, conservative and reproducible method to assess vaccine coverage. The method has been successfully transferred and standardized in several public health laboratories across Europe, North America, and Australia and used to screen thousands of isolates all over the world. Here we describe the sandwich ELISA method applied to assess the expression and cross-reactivity of fHbp, NHBA, and NadA in MenB isolates.

This is a preview of subscription content, log in via an institution.

Buying options

Protocol
USD   49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Springer Nature is developing a new tool to find and evaluate Protocols. Learn more

References

  1. Stephens DS, Greenwood B, Brandtzaeg P (2007) Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet 369:2196–2210

    Article  Google Scholar 

  2. Martin NG, Snape MD (2013) A multicomponent serogroup B meningococcal vaccine is licensed for use in Europe: what do we know, and what are we yet to learn? Exp Rev Vacc 12:837–858

    Article  CAS  Google Scholar 

  3. Wise J (2016) MenB vaccine programme cuts cases of meningitis and septicaemia in infants. BMJ 354:i4839

    Article  Google Scholar 

  4. Serruto D, Bottomley MJ, Ram S, Giuliani MM, Rappuoli R (2012) The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens. Vaccine 30(2):B87–B97

    Article  CAS  Google Scholar 

  5. Frasch CE, Borrow R, Donnelly J (2009) Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease. Vaccine 27(Suppl 2):B112–B116

    Article  CAS  Google Scholar 

  6. Donnelly J, Medini D, Boccadifuoco G et al (2010) Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci U S A 107(45):19490–19495

    Article  CAS  Google Scholar 

Download references

Acknowledgments, Sponsorship, and Conflict of Interest

Material and support for this study were provided by GlaxoSmithKline Biologicals SA. GlaxoSmithKline Biologicals SA was involved in analysis and interpretation of data. GlaxoSmithKline Biologicals SA was provided the opportunity to review a preliminary version of the manuscript for factual accuracy, but we are solely responsible for final content and interpretation. We received no financial support or other form of compensation related to the development of the manuscript.

G.B., B.B., E.M., C.G., M.A., and M.M.G. are currently employed by the GSK group of companies.

G.B., B.B., E.M., C.G., M.A., and M.M.G. participated in the drafting and revision of the manuscript.

This is a methodology description, no data are included in this publication.

This work was sponsored by Novartis Vaccines and Diagnostics Srl; in March 2015 the Novartis non-influenza Vaccines business was acquired by the GSK group of companies. The sponsor was involved in all stages of the study conduct and analysis.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Giuseppe Boccadifuoco .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Science+Business Media, LLC, part of Springer Nature

About this protocol

Check for updates. Verify currency and authenticity via CrossMark

Cite this protocol

Boccadifuoco, G., Brunelli, B., Mori, E., Agnusdei, M., Gianfaldoni, C., Giuliani, M.M. (2019). Meningococcal Antigen Typing System (MATS): A Tool to Estimate Global Coverage for 4CMenB, a Multicomponent Meningococcal B Vaccine. In: Seib, K., Peak, I. (eds) Neisseria meningitidis. Methods in Molecular Biology, vol 1969. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-9202-7_14

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-9202-7_14

  • Published:

  • Publisher Name: Humana Press, New York, NY

  • Print ISBN: 978-1-4939-9201-0

  • Online ISBN: 978-1-4939-9202-7

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics